Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024.
- DOI
- 10.1111/cts.70729
- Published
- 2026 Sep
- Container
- Clinical and translational science
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/cts.70729,
title = {Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024.},
author = {Yu J and Petrie I and Argon S and Owens K and Ragueneau-Majlessi I},
year = {2026},
journal = {Clinical and translational science},
doi = {10.1111/cts.70729},
url = {https://doi.org/10.1111/cts.70729}
}RIS
TY - JOUR TI - Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024. AU - Yu J AU - Petrie I AU - Argon S AU - Owens K AU - Ragueneau-Majlessi I PY - 2026 JO - Clinical and translational science DO - 10.1111/cts.70729 UR - https://doi.org/10.1111/cts.70729 ER -
APA
J, Y., I, P., S, A., K, O., & I, R. (2026). Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024.. Clinical and translational science. https://doi.org/10.1111/cts.70729
Source records
- pubmed · retrieved 2026-09-26T17:27:53.498Z
- europe-pmc · retrieved 2026-09-26T17:27:53.511Z
- doaj · retrieved 2026-09-26T17:27:53.516Z